InflaRx N.V. (HAM:IF0) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares and pre-funded warrants Closed: US$30M raised · US$2 a share · Warrants at US$0.001 · Guggenheim Securities, LLC +2 Dealers: Guggenheim Securities, LLC (lead), H.C. Wainwright & Co. (co-lead), Lucid Capital Markets, LLC (co-lead) Use of proceeds: Clinical development of pipeline candidates including vilobelimab and INF904, and general corporate purposes | Feb 18, 2025 |